Trial Profile

ERICA: Phase 2 Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 22 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CEP 11981 (Primary) ; Nivolumab (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use
Acronyms ERICA

Most Recent Events

18 Sep 2023 Status changed from active, no longer recruiting to discontinued.
08 Sep 2021 Status changed from recruiting to active, no longer recruiting.
21 Sep 2020 Status changed from suspended to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com